Roche Diagnostics hires Sause as new CEO of North America
Matthew Sause, 42, returns to Roche Diagnostics Corp., where he worked for 17 years before leaving briefly this year for a senior position at Gilead Sciences.
Matthew Sause, 42, returns to Roche Diagnostics Corp., where he worked for 17 years before leaving briefly this year for a senior position at Gilead Sciences.
Jack Phillips, who has led Roche Diagnostics’ North American operations in Indianapolis since 2010, will become chief operating officer of Accelerate Diagnostics in Tucson.
Spark Therapeutics Inc. will give Roche Holding a chance to make up ground in a field where single treatments may command more than $1 million. It also snaps up an asset that rivals like Novartis might have coveted.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The “Roche Academy” will provide mentors, internships and special curriculum to biology and chemistry undergrads, along with financial incentives and a job offer after graduation.
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
Roche Group is rolling out a new blood-glucose meter and a savings program for test strips, which it says it will make diabetes care more affordable.
Vince Wong hadn’t planned to come back to the state, but with parents in their 80s and young children at home, “it felt like a great opportunity both from a professional and a personal perspective.”
Two Indianapolis-based subsidiaries of Swiss pharmaceutical giant Roche Group are accusing a group of pharmacies and supply houses of engaging in an elaborate scheme to defraud Roche of millions of dollars worth of sales on diabetes test strips.
The Swiss-based company confirmed Wednesday morning the cuts are part of a U.S. restructuring that will result in eliminating 133 full-time workers and 24 contractors.
Since 2012, the company has built five buildings, refurbished existing buildings, made upgrades to IT infrastructure, and increased investments in its diabetes care manufacturing technology.
The future of U.S. health care will be about precision and parsimony. And Roche Diagnostics Corp. think its new line of DNA-level testing machines are just what the doctor ordered.
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
Roche Diagnostics Corp. saw a stunning 13-percent boost in sales in its North American diabetes care business during the first quarter, although neither company management nor stock analysts expect that trend to last.
Roche could enjoy a huge increase in sales of its HPV tests if all doctors and women followed a recommendation issued last week by an advisory committee at the FDA. But wrinkles in the U.S. health care system still present several big obstacles.
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin.
Roche’s diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.